Using the drug repositioning approach to develop a novel therapy, tipepidine hibenzate sustained-release tablet (TS-141), for children and adolescents with attention-deficit/hyperactivity disorder

BACKGROUND: Asverin® (tipepidine hibenzate) has been used as an antitussive for > 50 years in Japan. Studies revealed that tipepidine modulates monoamine levels, by inhibiting G-protein-activated inwardly rectifying potassium (GIRK) channels, expecting the potential therapeutic effects of tipepid...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Takuya, Yamashita, Yushiro, Tomoda, Akemi, Okada, Takashi, Umeuchi, Hideo, Iwamori, Saki, Shinoda, Satoru, Mizuno-Yasuhira, Akiko, Urano, Hidetoshi, Nishino, Izumi, Saito, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653993/
https://www.ncbi.nlm.nih.gov/pubmed/33167920
http://dx.doi.org/10.1186/s12888-020-02932-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653993/
https://www.ncbi.nlm.nih.gov/pubmed/33167920
http://dx.doi.org/10.1186/s12888-020-02932-2

Ejemplares similares